NO2539366T3 - - Google Patents

Info

Publication number
NO2539366T3
NO2539366T3 NO11713058A NO11713058A NO2539366T3 NO 2539366 T3 NO2539366 T3 NO 2539366T3 NO 11713058 A NO11713058 A NO 11713058A NO 11713058 A NO11713058 A NO 11713058A NO 2539366 T3 NO2539366 T3 NO 2539366T3
Authority
NO
Norway
Application number
NO11713058A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2539366T3 publication Critical patent/NO2539366T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • G01N2800/302Schizophrenia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/38Pediatrics
    • G01N2800/385Congenital anomalies
    • G01N2800/387Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
NO11713058A 2010-02-26 2011-02-25 NO2539366T3 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30863810P 2010-02-26 2010-02-26
US40626010P 2010-10-25 2010-10-25
PCT/IB2011/050826 WO2011104696A1 (en) 2010-02-26 2011-02-25 Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

Publications (1)

Publication Number Publication Date
NO2539366T3 true NO2539366T3 (enExample) 2018-04-07

Family

ID=44227520

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11713058A NO2539366T3 (enExample) 2010-02-26 2011-02-25

Country Status (20)

Country Link
US (4) US8632776B2 (enExample)
EP (1) EP2539366B1 (enExample)
JP (1) JP5894939B2 (enExample)
CN (3) CN102869680B (enExample)
AU (1) AU2011219414B2 (enExample)
CA (1) CA2789963C (enExample)
CY (1) CY1120014T1 (enExample)
DK (1) DK2539366T3 (enExample)
ES (1) ES2661925T3 (enExample)
HR (1) HRP20180230T8 (enExample)
HU (1) HUE038313T2 (enExample)
LT (1) LT2539366T (enExample)
NO (1) NO2539366T3 (enExample)
PL (1) PL2539366T3 (enExample)
PT (1) PT2539366T (enExample)
RS (1) RS57029B1 (enExample)
RU (1) RU2555526C2 (enExample)
SI (1) SI2539366T1 (enExample)
SM (1) SMT201800044T1 (enExample)
WO (1) WO2011104696A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
NO2539366T3 (enExample) 2010-02-26 2018-04-07
US10989718B2 (en) * 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
SI2804878T1 (sl) * 2012-01-20 2018-12-31 Genzyme Corporation Protitelesa proti-CXCR3
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015075011A1 (en) 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
SMT202100263T1 (it) * 2014-07-10 2021-07-12 Eisai R&D Man Co Ltd Anticorpi leganti protofibrille a-beta migliorati
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック, インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
WO2016137947A1 (en) * 2015-02-24 2016-09-01 Rpeptide, Llc Anti-amyloid-beta antibodies
EP3091087A1 (en) 2015-05-08 2016-11-09 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
AU2016295650A1 (en) 2015-07-21 2018-01-25 Bioarctic Neuroscience Ab Method for treatment of traumatic brain injury targeting aggregated peptides
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
KR20180094876A (ko) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
HK1259325A1 (zh) 2015-11-09 2019-11-29 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
WO2017207739A1 (en) 2016-06-02 2017-12-07 Medimmune Limited Antibodies to alpha-synuclein and uses thereof
MA45684A (fr) * 2016-07-14 2019-05-22 Bioarctic Neuroscience Ab Protéine d'apport du cerveau
US12071472B2 (en) 2016-07-18 2024-08-27 The University Of British Columbia Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10889635B2 (en) * 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
BR112018016717A2 (pt) 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
KR102014066B1 (ko) * 2017-01-06 2019-10-21 에이비엘바이오 주식회사 항 α-syn 항체 및 그 용도
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
BR112019016374A2 (pt) * 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
WO2018191786A1 (en) * 2017-04-21 2018-10-25 Implicit Bioscience Pty Ltd Cd 14 antagonist antibodies for treating neurodegenerative diseases
WO2018204352A1 (en) * 2017-05-01 2018-11-08 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
CN110869763B (zh) 2017-05-16 2022-07-29 安培里翁公司 错误折叠tau蛋白质的检测
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
US11098108B2 (en) 2017-08-02 2021-08-24 Stressmarq Biosciences Inc. Antibody binding active alpha-synuclein
US11155608B2 (en) 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
RU2657763C1 (ru) * 2017-09-12 2018-06-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики болезни паркинсона
AU2018370279B2 (en) * 2017-11-17 2022-11-03 Abl Bio Inc. Antibodies to a-synuclein and uses thereof
BR112020011875A2 (pt) 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EP4273882A3 (en) 2017-12-19 2024-01-03 Chase Therapeutics Corporation Method for assessing a synucleinopathy
US20200309796A1 (en) * 2017-12-21 2020-10-01 H. Lundbeck A/S Assay, method and treatment of alpha-synucleinopathies
CN109957547A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用
CN109957546A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用
EP3773692A4 (en) * 2018-04-04 2022-03-16 University of Florida Research Foundation, Inc. MATERIALS AND METHODS FOR TREATMENT OF LEWY BODY DEMENTIA
WO2019217833A1 (en) * 2018-05-10 2019-11-14 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
US20210324056A1 (en) 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CA3111907A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
JP7196311B2 (ja) * 2018-12-12 2022-12-26 ウーシー バイオロジクス アイルランド リミテッド 抗tim-3抗体とその利用
RU2703430C1 (ru) * 2018-12-13 2019-10-16 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
EP3946266A4 (en) * 2019-03-28 2023-07-12 The Chinese University Of Hong Kong SUMO PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CN114341343B (zh) * 2019-04-30 2024-11-15 才思治疗公司 α-突触核蛋白测定
US20220291240A1 (en) * 2019-08-27 2022-09-15 The Johns Hopkins University Biomarkers for neurodegenerative disorders
IL294408A (en) 2019-12-31 2022-08-01 Chase Therapeutics Corp Kinases as biomarkers for neurodegenerative conditions
CN111171152B (zh) * 2020-01-15 2023-04-18 吉林医药学院 Pcsk9抗体及其制备方法和应用
NL2025332B1 (en) * 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
MD4172199T2 (ro) * 2020-06-26 2025-09-30 Bioarctic Ab Anticorpi care leagă protofibrila de alfa-sinucleină
US20230365665A1 (en) 2020-09-17 2023-11-16 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
US20250163135A1 (en) 2021-07-09 2025-05-22 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
JP2024532438A (ja) 2021-08-30 2024-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗Aβプロトフィブリル抗体の皮下製剤及びその使用方法
CA3243435A1 (en) 2022-02-02 2023-08-10 Eisai R&D Management Co., Ltd. TREATMENT METHODS USING THE P-TAU181 LEVEL
JP2023132247A (ja) * 2022-03-10 2023-09-22 公立大学法人大阪 シヌクレイノパシー検出用バイオマーカー及びその利用
CN117430686B (zh) * 2022-07-22 2025-07-01 深圳市安群生物工程有限公司 α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用
CN116589567B (zh) * 2022-11-30 2024-03-19 西南大学 马铃薯x病毒单克隆抗体pvx-2及其应用
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002053A2 (en) 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
GEP20104991B (en) * 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1989330A4 (en) 2006-01-31 2009-10-21 Elan Pharm Inc ALPHA-SYNUCLEINE KINASE
PL2004688T5 (pl) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CN101161245B (zh) * 2007-11-29 2011-11-09 首都医科大学宣武医院 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
PL2448968T3 (pl) 2009-06-29 2021-09-13 Bioarctic Ab Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta
NO2539366T3 (enExample) 2010-02-26 2018-04-07

Also Published As

Publication number Publication date
CA2789963C (en) 2019-09-03
JP2013525266A (ja) 2013-06-20
US20130309251A1 (en) 2013-11-21
HRP20180230T8 (hr) 2021-04-30
US8632776B2 (en) 2014-01-21
US8968734B2 (en) 2015-03-03
PL2539366T3 (pl) 2018-06-29
AU2011219414A1 (en) 2012-09-06
CN102869680A (zh) 2013-01-09
SMT201800044T1 (it) 2018-05-02
HUE038313T2 (hu) 2018-10-29
US9084832B2 (en) 2015-07-21
RU2555526C2 (ru) 2015-07-10
US20140363447A1 (en) 2014-12-11
DK2539366T3 (en) 2018-02-05
US20120308572A1 (en) 2012-12-06
CN102869680B (zh) 2016-10-05
ES2661925T3 (es) 2018-04-04
WO2011104696A1 (en) 2011-09-01
JP5894939B2 (ja) 2016-03-30
CY1120014T1 (el) 2018-12-12
EP2539366A1 (en) 2013-01-02
US20150139900A1 (en) 2015-05-21
US8859501B2 (en) 2014-10-14
CN106397588B (zh) 2020-09-08
EP2539366B1 (en) 2017-11-08
LT2539366T (lt) 2018-04-25
CN106397588A (zh) 2017-02-15
CN110655573A (zh) 2020-01-07
CA2789963A1 (en) 2011-09-01
HRP20180230T1 (hr) 2018-03-09
CN110655573B (zh) 2023-07-18
PT2539366T (pt) 2018-02-13
AU2011219414B2 (en) 2014-11-20
SI2539366T1 (en) 2018-05-31
RU2012140954A (ru) 2014-04-10
RS57029B1 (sr) 2018-05-31

Similar Documents

Publication Publication Date Title
BR112013008959A2 (enExample)
BR112012019354A2 (enExample)
BR112012024897A2 (enExample)
NO2539366T3 (enExample)
BR112012025307A2 (enExample)
BR112012017960A2 (enExample)
BR112012002126A2 (enExample)
BR112012025482A2 (enExample)
BR112013006400A2 (enExample)
BR112012031826A2 (enExample)
BR112012025577A2 (enExample)
BR112012023249A2 (enExample)
BR112012016456A2 (enExample)
BR112012018256A2 (enExample)
BR112012025308A2 (enExample)
BR112013010949A2 (enExample)
BR112012023265A2 (enExample)
BR112012024872A2 (enExample)
BR112013012726A2 (enExample)
BR112012022788A2 (enExample)
BR112012016895A2 (enExample)
BR112012023446A2 (enExample)
BR112013007731A2 (enExample)
BR112012024658A2 (enExample)
BR112012023744A2 (enExample)